Asia
Singapore scientists’ discovery could hold the key to novel treatments for the symptoms of mosquito-borne diseases
Portfolio of Products, Education and Training to Help Surgeons Handle Challenging Reoperations
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Eli Lilly just signed a license deal with Tokyo’s Chugai Pharmaceutical Co. for OWL833, Chugai’s oral non-peptidic GLP-1 receptor agonist. It is Phase 1-ready being evaluated for type 2 diabetes.
Ground-breaking technology unlocks rapid and simple label-free 3D and 4D live cell imaging
As the acquisition of Dublin-based Shire by Japan-based Takeda Pharmaceutical edges forward, yet another major Takeda shareholder has spoken out in opposition to the deal.
Aridis Pharmaceuticals, headquartered in San Jose, California, announced it had added broad patent coverage of two of its product candidate monoclonal antibodies.
Tokyo-based Astellas Pharma announced that its roxadustat met its primary endpoints in the Phase III ALPS clinical trial in chronic kidney disease (CKD) patients with anemia not on dialysis. The focus of the drug is on anemia.
Astellas Pharma Inc. today announced that roxadustat, an inhibitor of hypoxia inducible factor (HIF) prolyl hydroxylase activity, met its primary endpoints in the Phase 3 ALPS study
Clinical data generated for submission process to be presented at international scientific congress in 2018
PRESS RELEASES